CME Factor-Based Stock Analysis

CME Group (CME) received an 81% rating from Validea's Multi-Factor Investor model, based on Pim van Vliet's low-volatility strategy, indicating 'some interest' for its underlying fundamentals and valuation. The model, which targets low volatility stocks with strong momentum and high net payout yields, found CME to pass criteria for market capitalization and low standard deviation. However, the large-cap investment services firm showed neutral results for both momentum and net payout yield within this quantitative framework.

Analysis

CME Group Inc. (CME) scored an 81% rating under Validea's Multi-Factor Investor model, which is based on Pim van Vliet's strategy of targeting low-volatility stocks with strong momentum and high net payout yields. This score indicates a degree of interest from the quantitative screen. The analysis highlights that CME, a large-cap growth stock, successfully meets the model's criteria for market capitalization and, critically, for low standard deviation, aligning with the strategy's core preference for conservative equities. However, CME's profile is mixed, as it registered a 'NEUTRAL' rating for both 'Twelve Minus One Momentum' and 'Net Payout Yield,' suggesting its recent price performance and capital return profile are not compelling enough to be considered strengths under this framework. Significantly, despite the 81% score, the stock received a 'FAIL' on its 'FINAL RANK', implying that it does not meet all the necessary combined criteria to pass the strategy's final filter.

Key Decisions for Investors

• Investors prioritizing a low-volatility mandate may find CME's 'PASS' on the standard deviation metric attractive, as it aligns with the core of the conservative factor strategy highlighted.
• Traders and investors seeking strong momentum or high capital returns should note that CME screens as 'NEUTRAL' on both momentum and net payout yield, suggesting it may underperform peers on these specific factors.
• Despite a favorable 81% score, the 'FAIL' on the model's final rank warrants caution, indicating that the stock does not fully align with the quantitative strategy's requirements and is not a clear-cut buy signal even for this factor profile.